Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: single center cohort study of 685 patients https://doi.org/10.1016/j.jtauto.2021.100086 From March 3 rd to May 7 th, 685 patients were included for analysis (58.4% males, mean age 68.9 years). Patients… Continue reading "(23 Feb 2021) Tocilizumab & methylprednisolone- showed significant impact on survival"
Tocilizumab Treatment in Critically Ill Patients with COVID-19: A Retrospective Observational Study https://doi.org/10.1016/j.ijid.2021.02.057 More tocilizumab-treated patients required mechanical ventilation (44/55, 80%) compared to non-treated patients (15/41, 37%; p<0.001). Of 55 patients treated with tocilizumab, 32 (58%) were on mechanical ventilation… Continue reading "(21 Feb 2021) Tocilizumab- associated with reduced mortality"
Safety and Efficacy of Tocilizumab in the Treatment of Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia: A Retrospective Cohort Study https://doi.org/10.4103/ijmm.IJMM_20_298 A total of 20 patients received TCZ during the study period. The median age was 54 years (95% confidence interval… Continue reading "(17 Feb 2021) Tocilizumab- reduction in ICU stay and ventilatory care need"
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial https://www.medrxiv.org/content/10.1101/2021.02.11.21249258v1 NCT04381936 RECOVERY Trial-Between 23 April 2020 and 24 January 2021, 4116 adults were included in the assessment of tocilizumab, including 562… Continue reading "(11 Feb 2021) Tocilizumab- improved survival and other clinical outcomes"
Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India https://www.medrxiv.org/content/10.1101/2021.02.04.21249959v1 Out of 2831 admitted patients, 515 (24.3% females) were administered TCZ and steroids. Median age of the… Continue reading "(06 Feb 2021) Tocilizumab- Combination therapy of TCZ and Steroids is likely to be safe and effective"
Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis https://doi.org/10.1093/ofid/ofaa598 This was an observational retrospective study of hospitalized adult patients with confirmed coronavirus disease 2019 (COVID-19). The intervention group comprised patients who received tocilizumab; the… Continue reading "(05 Feb 2021) Tocilizumab- associated with reduced hazards of death"
Administration of tocilizumab to patients with high concentrations of IL-6 in the course of COVID-19 is associated with a better prognosis https://www.medrxiv.org/content/10.1101/2021.01.28.21249932v1 Patients treated with TCZ were balanced compared to non-TCZ regarding gender, age, BMI, and prevalence of coexisting conditions.… Continue reading "(01 Feb 2021) Tocilizumab- associated with reduced mortality and faster clinical improvement in patients with higher IL-6"
Tocilizumab for COVID-19 Acute Respiratory Distress Syndrome: Outcomes Assessment Using the WHO Ordinal Scale https://doi.org/10.7759/cureus.12290 An observational study was conducted from Feb 2020 to May 2020 on COVID-19 ARDS patients with hyperinflammation. A total of 244 patients with COVID-19 were… Continue reading "(30 Jan 2021) Tocilizumab- study supports the use of tocilizumab in COVID-19 ARDS patients"
Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain https://doi.org/10.1080/17512433.2021.1875819 162 patients (median age 64 years; 70.4% male) were included in a retrospective cohort in Spain. At time of TCZ administration, 48.1%… Continue reading "(28 Jan 2021) Tocilizumab- incidence of secondary nosocomial infections was high"
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial https://doi.org/10.1001/jama.2021.0202 NCT04403685-A total of 129 patients were enrolled (mean age 57 (SD 14) years; 68% men) and all completed… Continue reading "(22 Jan 2021) Tocilizumab- TCZ plus SoC was not superior in improving clinical outcomes at 15 days"
